Skip to main content

Highlights:

  • Pharming has received a formal European Commission (EC) decision on the approval of a new RUCONEST® license extension in Europe
  • European Commission decision was received six weeks earlier than expected
  • The extension of the indication means that RUCONEST® is now approved for the treatment of acute angioedema attacks in adults, adolescents, and children (aged two years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in Europe

We are pleased to receive approval from the European Commission and to be able to offer RUCONEST® as a treatment for acute HAE attacks in all patients aged two years and above.

- Sijmen de Vries - CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline